Open an account

CV Sciences

CVSI · OTC

$0.01−$0.0012 (−10.71%)TodayMarket closed ·
Prev close $0.0112

About CVSI

CV Sciences, Inc. engages in the development, manufacture, and sale of herbal supplements, CBD products and plant-based food products. The company is headquartered in San Diego, California and currently employs 42 full-time employees. The company went IPO on 2018-10-04. The firm develops, manufactures, markets and sells herbal supplements, CBD products and plant-based food products under +PlusCBD, +PlusHLTH, Cultured Foods, and Lunar Fox brands in the healthcare market sector, including nutraceutical, beauty care, specialty foods, and pet products. Its hemp extracts, and other science-backed, natural ingredients and products are sold through a range of sales channels from business-to-business (B2B) to business-to-consumer (B2C). Its +PlusCBD line of products are available in softgels, tinctures, topicals, and gummies. Its Cultured Foods and Lunar Fox cater to individuals seeking vegan, gluten-free, or flexitarian options for a nutritious and satisfying culinary experience. Its +PlusHLTH is a line of cannabinoid-free supplements delivering targeted formulations for optimized health, improved performance and increased vitality.

Employees
42
Headquarters
San Diego, California
Listed
Oct 4, 2018
Sector
Consumer Staples
Industry
Personal Care Products
Website
cvsciences.com

CVSI key statistics

Market cap
2.26M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
313.00K
Volume
2.36M
Open price
$0.0112
High today
$0.012
Low today
$0.0098
52 Week high
$0.10
52 Week low
$0.0112

CV Sciences (CVSI) at a glance

CV Sciences (CVSI) last traded at $0.01, with a market cap of 2.26M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.0098 and $0.012. The current price is 2.0% above the day's low and 16.7% below its high.

Volume so far is 2.36M shares, above the average of 313.00K shares a day.

Over the past year CV Sciences has ranged from $0.0112 to $0.10, and now sits -1% of the way up that range.

CV Sciences met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q4 FY25 it reported $0.00 per share against an estimate of $0.00.

CVSI earnings

Earnings per share, reported against the analyst estimate

Didn’t beat the estimate in any of the last 8 quarters.

  1. Q2 FY23: reported -$0.01 per share against an estimate of $0.00
  2. Q3 FY23: reported $0.00 per share against an estimate of $0.00
  3. Q4 FY23: reported -$0.01 per share against an estimate of $0.00
  4. Q1 FY24: reported $0.00 per share against an estimate of $0.00
  5. Q2 FY24: reported $0.00 per share against an estimate of $0.00
  6. Q3 FY24: reported $0.00 per share against an estimate of $0.00
  7. Q4 FY24: reported $0.00 per share against an estimate of $0.00
  8. Q4 FY25: reported $0.00 per share against an estimate of $0.00

CVSI news

  • CV Sciences Q2 2026 Earnings Call Transcript

  • Press releaseACCESS Newswire

    CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results

  • Press releaseACCESS Newswire

    CV Sciences, Inc. to Announce Second Quarter 2026 Results on August 13, 2026

  • CV Sciences Reports Q1 2026 Results: Full Earnings Call Transcript

  • Press releaseACCESS Newswire

    CV Sciences, Inc. Reports First Quarter-End 2026 Financial Results

  • Press releaseACCESS Newswire

    CV Sciences, Inc. To Announce First Quarter 2026 Results On May 14, 2026

  • Press releaseACCESS Newswire

    CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results

  • Press releaseACCESS Newswire

    CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026

Similar companies

Companies in the same industry as CV Sciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.